Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 20;12(10):1652.
doi: 10.3390/life12101652.

Nutraceuticals for Complementary Treatment of Multisystem Inflammatory Syndrome in Children: A Perspective from Their Use in COVID-19

Diego Estrada-Luna  1 , Elizabeth Carreón-Torres  2 , Susana González-Reyes  3 , María Fernanda Martínez-Salazar  4 , María Araceli Ortiz-Rodríguez  5 , Esther Ramírez-Moreno  6 , José Arias-Rico  1 , Angélica Saraí Jiménez-Osorio  1
Affiliations
Review

Nutraceuticals for Complementary Treatment of Multisystem Inflammatory Syndrome in Children: A Perspective from Their Use in COVID-19

Diego Estrada-Luna et al. Life (Basel). .

Abstract

Multisystem inflammatory syndrome in children (MIS-C) has been widely reported in some children diagnosed with SARS-CoV-2. Clinical signs of MIS-C are manifested at 2 to 4 weeks after SARS-CoV-2 infection, where elevated biomarkers of inflammation and cardiac dysfunction are the hallmark of this syndrome when infection or exposure to SARS-CoV-2 has been confirmed. However, after two years of acknowledgment, MIS-C treatment is still under research to reach safety and effectiveness in the acute phase in children. Therefore, in this review, we discuss the potential use of natural compounds with antioxidant and anti-inflammatory effects to reduce collateral damage caused by hyperinflammation in MIS-C pathology for new research in treatment and interventions.

Keywords: children; multisystem inflammatory syndrome; nutraceutical compounds.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
MIS-C case definition according to international guidelines. Abbreviations: AAP, American Academy of Pediatrics; ACR, American College of Rheumatology; CDC, Centers for Disease Control and Prevention; NS, no specified; PCR, polymerase chain reaction, RCPCH, Royal College of Paediatrics and Child Health; WHO, World Health Organization.
Figure 2
Figure 2
Effect of pharmacological treatment for MIS-C on clinical signs at admission, organ dysfunction and inflammation. Downward arrows indicate the decrease in signs, symptoms, and markers of inflammation by treatment with aspirin (trapezoid), IVIG (circle), and steroids (hexagon). Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ICU, intensive care unit; IVIG, intravenous immunoglobulin.
Figure 3
Figure 3
Hyperinflammatory state and oxidative stress in immunological response in MIS-C after SARS-CoV-2 infection.
Figure 4
Figure 4
Potential nutraceutical compounds for complementary treatment of MIS-C by its antioxidant and anti-inflammatory properties to regulate cytokine storm and reduce organ damage.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Castagnoli R., Votto M., Licari A., Brambilla I., Bruno R., Perlini S., Rovida F., Baldanti F., Marseglia G.L. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr. 2020;174:882–889. doi: 10.1001/jamapediatrics.2020.1467. - DOI - PubMed
    1. Pouletty M., Borocco C., Ouldali N., Caseris M., Basmaci R., Lachaume N., Bensaid P., Pichard S., Kouider H., Morelle G., et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): A multicentre cohort. Ann. Rheum. Dis. 2020;79:999–1006. doi: 10.1136/annrheumdis-2020-217960. - DOI - PMC - PubMed
    1. Ramcharan T., Nolan O., Lai C.Y., Prabhu N., Krishnamurthy R., Richter A.G., Jyothish D., Kanthimathinathan H.K., Welch S.B., Hackett S., et al. Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital. Pediatr. Cardiol. 2020;41:1391–1401. doi: 10.1007/s00246-020-02391-2. - DOI - PMC - PubMed
    1. Toubiana J., Poirault C., Corsia A., Bajolle F., Fourgeaud J., Angoulvant F., Debray A., Basmaci R., Salvador E., Biscardi S., et al. Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19 pandemic in Paris, France: Prospective observational study. BMJ. 2020;369:m2094. doi: 10.1136/bmj.m2094. - DOI - PMC - PubMed
    1. Whittaker E., Bamford A., Kenny J., Kaforou M., Jones C., Shah P., Ramnarayan P., Fraisse A., Miller O., Davies P., et al. Clinical Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2. JAMA. 2020;324:259–269. doi: 10.1001/jama.2020.10369. - DOI - PMC - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources